10X Genomics Inc (TXG) - Total Liabilities
Based on the latest financial reports, 10X Genomics Inc (TXG) has total liabilities worth $241.03 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TXG cash flow metrics to assess how effectively this company generates cash.
10X Genomics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how 10X Genomics Inc's total liabilities have evolved over time, based on quarterly financial data. Check TXG financial resilience to evaluate the company's liquid asset resilience ratio.
10X Genomics Inc Competitors by Total Liabilities
The table below lists competitors of 10X Genomics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Baoding Lucky Innovative Materials Co Ltd
SHE:300446
|
China | CN¥5.24 Billion |
|
CHINA CONCH VENT. HD -01
F:68C
|
Germany | €33.40 Billion |
|
Droneshield Ltd
AU:DRO
|
Australia | AU$38.99 Million |
|
Wuhan Yangtze Communication Industry Group Co Ltd
SHG:600345
|
China | CN¥1.07 Billion |
|
Alpha Metallurgical Resources Inc
NYSE:AMR
|
USA | $753.17 Million |
|
Tangshan Sanyou Chemical Industries Co Ltd
SHG:600409
|
China | CN¥11.24 Billion |
|
Yankershop Food Co Ltd
SHE:002847
|
China | CN¥1.90 Billion |
|
Dalian Bio-Chem Co Ltd
SHG:603360
|
China | CN¥1.58 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down 10X Genomics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is 10X Genomics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 10X Genomics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 10X Genomics Inc (2017–2024)
The table below shows the annual total liabilities of 10X Genomics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $208.50 Million | -6.96% |
| 2023-12-31 | $224.10 Million | +0.39% |
| 2022-12-31 | $223.24 Million | +10.92% |
| 2021-12-31 | $201.26 Million | +5.78% |
| 2020-12-31 | $190.27 Million | +2.38% |
| 2019-12-31 | $185.84 Million | -46.02% |
| 2018-12-31 | $344.30 Million | +83.02% |
| 2017-12-31 | $188.12 Million | -- |
About 10X Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and … Read more